Research advances of noninvasive diagnosis of fibrotic non-alcoholic steatohepatitis

Gong FENG; Rongyao KONG; Jiaxue WANG; Tianyue WU; Xiaohui WU; Juning WANG; Qinqin YAN; Man MI

doi:10.12449/JCH241125

Volume 40 Issue 11

Nov. 2024

Turn off MathJax

Article Contents

Abstract

References

Article Navigation > Journal of Clinical Hepatology > 2024 > 40(11): 2293-2299

PDF( 694 KB)

Research advances of noninvasive diagnosis of fibrotic non-alcoholic steatohepatitis

DOI: 10.12449/JCH241125

Gong FENG^{1a, 2
,
,
,},
Rongyao KONG^1b,
Jiaxue WANG^1b,
Tianyue WU^1c,
Xiaohui WU^1b,
Juning WANG³,
Qinqin YAN^1a,
Man MI^{1a
,
,
,}

1a.
Institute of General Practice，Xi’an Medical University，Xi’an 710021，China
1b.
School of Clinical Medicine，Xi’an Medical University，Xi’an 710021，China
1c.
School of General Practice，Xi’an Medical University，Xi’an 710021，China
2.
Department of Infectious Diseases，The First Affiliated Hospital of Xi’an Jiaotong University，Xi’an 710061，China
3.
School of Medicine，Xi’an Peihua University，Xi’an 710199，China

Research funding:

Projects of Shaanxi Provincial Department of Education (23JK0646);

Natural Science Basic Research Program of Shaanxi (2023-JC-YB-699);

Xi’an Medical University Scientific Research Capacity Enhancement Program (2022NLTS098);

Young Talent Support Program of Xi’an City Association for Science and Technology (959202413081)

More Information

Corresponding author: FENG Gong， 2543073495@qq.com （ORCID： 0000-0001-5394-0029）; MI Man， 853002274@qq.com （ORCID： 0000-0001-7408-5113）
Received Date: 2024-02-01
Accepted Date: 2024-04-19
Published Date: 2024-11-25

Abstract

Abstract

A subset of patients with non-alcoholic fatty liver disease （NAFLD） can progress to nonalcoholic steatohepatitis （NASH）. When NASH reaches a fibrosis degree of F≥2 and a NAS score of≥4， this stage of NASH is referred to as fibrotic NASH， which is a key focus in clinical drug trials. Currently， liver biopsy is the gold standard for assessing the histological changes of the liver， but its clinical application is limited by its invasiveness， and therefore， it is of particular importance to develop noninvasive detection methods for fibrotic NASH. This article summarizes the recent research achievements in novel noninvasive diagnostic methods for fibrotic NASH and elaborates on these new diagnostic methods for predicting fibrotic NASH in terms of current status， challenges faced， and prospects for future development.
- Non-alcoholic Fatty Liver Disease,
- Fibrosis,
- Biomarkers,
- Diagnosis,
- Artificial Intelligence

FullText(HTML)

肝细胞癌（HCC）是临床常见的恶性肿瘤之一。HCC早期治疗以手术切除为主，但侵袭性HCC的治疗策略目前选择有限，索拉非尼、仑伐替尼及程序性细胞死亡受体1及其配体免疫抑制剂治疗HCC的效果不佳，临床有效率不足30%。因此，亟需进一步探究HCC的发病机制与治疗靶点。随着基因组学研究的发展，对HCC肿瘤生物学的认识逐渐深入，但HCC的泛素化特征尚不明晰。本研究旨在揭示HCC的泛素化特征，并探寻可指导侵袭性HCC临床诊断和治疗的潜在生物标志物。

陆军军医大学第一附属医院（重庆西南医院）谢传明教授、张雷达教授与重庆医科大学侯宇教授等通过对85例HCC患者肿瘤及相邻正常肝组织进行蛋白质组学、磷酸化修饰组学和泛素化修饰组学测序与分析发现，COL4A1、LAMC1和LAMA4在无病生存期较差患者中高表达。磷酸化与泛素化修饰在代谢和转移相关信号通路中存在关联。利用泛素化组学和蛋白质组学数据对HCC进行分子分型，发现具有不同临床特征的3个亚型：S-‍Ⅰ、S-‍Ⅱ和S-Ⅲ。S-‍Ⅰ亚型以代谢相关蛋白高表达为特征，预后最好；S-Ⅲ亚型与增殖/转移信号通路密切相关，预后最差，表现为总生存期最短和复发率最高；而S-‍Ⅱ亚型则介于两者之间。研究发现，生物标志物TUBA1A、BHMT2、BHMT和ACY1的表达表现出不同的泛素化水平，与HCC患者预后不良密切相关，表明靶向这些蛋白质或其泛素化修饰蛋白可能对临床治疗有益。此外，研究证实TUBA1A K370去泛素化可驱动HCC发生与转移，这主要归因于AKT介导的USP14激活。TUBA1A K370去泛素化标志着一类高侵袭性HCC亚型。值得注意的是，靶向AKT-USP14-TUBA1A复合物可促进TUBA1A降解，并在体内阻断HCC发生。

总之，本研究从泛素化组学、磷酸化组学和蛋白质组学角度对HCC进行了全面的整合分析，该研究不仅加深了对HCC中泛素化特征的了解，并为开发新的HCC生物标志物和潜在的治疗靶点提供了依据。

摘译自LIN XT, LUO YD, MAO C, et al. Integrated ubiquitomics characterization of hepatocellular carcinomas[J]. Hepatology, 2024. DOI: 10.1097/HEP.0000000000001096. [Online ahead of print]

(陆军军医大学第一附属医院肝胆外科谢传明报道）

References(36)

References

[1]	MATTEONI CA, YOUNOSSI ZM, GRAMLICH T, et al. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity[J]. Gastroenterology, 1999, 116( 6): 1413- 1419. DOI: 10.1016/s0016-5085(99)70506-8.
[2]	WONG VW, EKSTEDT M, WONG GL, et al. Changing epidemiology, global trends and implications for outcomes of NAFLD[J]. J Hepatol, 2023, 79( 3): 842- 852. DOI: 10.1016/j.jhep.2023.04.036.
[3]	ANGULO P, KLEINER DE, DAM-LARSEN S, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease[J]. Gastroenterology, 2015, 149( 2): 389- 397. e 10. DOI: 10.1053/j.gastro.2015.04.043.
[4]	TIAN AP, YANG YF. Diagnosis of nonalcoholic fatty liver disease: The importance of pathology[J]. J Clin Hepatol, 2023, 39( 3): 491- 497. DOI: 10.3969/j.issn.1001-5256.2023.03.002. 田爱平, 杨永峰. 非酒精性脂肪性肝病诊断: 病理的重要性[J]. 临床肝胆病杂志, 2023, 39( 3): 491- 497. DOI: 10.3969/j.issn.1001-5256.2023.03.002.
[5]	CIARDULLO S, PERSEGHIN G. Trends in prevalence of probable fibrotic non-alcoholic steatohepatitis in the United States, 1999-2016[J]. Liver Int, 2023, 43( 2): 340- 344. DOI: 10.1111/liv.15503.
[6]	SCHUPPAN D, SURABATTULA R, WANG XY. Determinants of fibrosis progression and regression in NASH[J]. J Hepatol, 2018, 68( 2): 238- 250. DOI: 10.1016/j.jhep.2017.11.012.
[7]	RATZIU V, CHARLOTTE F, HEURTIER A, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease[J]. Gastroenterology, 2005, 128( 7): 1898- 1906. DOI: 10.1053/j.gastro.2005.03.084.
[8]	HUBMACHER D, APTE SS. ADAMTS proteins as modulators of microfibril formation and function[J]. Matrix Biol, 2015, 47: 34- 43. DOI: 10.1016/j.matbio.2015.05.004.
[9]	COREY KE, PITTS R, LAI M, et al. ADAMTSL2 protein and a soluble biomarker signature identify at-risk non-alcoholic steatohepatitis and fibrosis in adults with NAFLD[J]. J Hepatol, 2022, 76( 1): 25- 33. DOI: 10.1016/j.jhep.2021.09.026.
[10]	ROSA MD, MALAGUARNERA L. Chitinase 3 like-1: An emerging molecule involved in diabetes and diabetic complications[J]. Pathobiology, 2016, 83( 5): 228- 242. DOI: 10.1159/000444855.
[11]	JOHANSEN JS, CHRISTOFFERSEN P, MØLLER S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis[J]. J Hepatol, 2000, 32( 6): 911- 920. DOI: 10.1016/s0168-8278(00)80095-1.
[12]	MO HL, ZHUO CS, LYU XJ, et al. Clinical values of chitinase 3 like protein 1 in the diagnosis of liver fibrosis\r in patients with chronic liver diseases[J]. Lab Med Clin, 2020, 17( 7): 914- 917, 920. DOI: 10.3969/j.issn.1672-9455.2020.07.014. 莫慧玲, 卓传尚, 吕旭江, 等. 壳多糖酶3样蛋白1在肝纤维化分期中的诊断价值[J]. 检验医学与临床, 2020, 17( 7): 914- 917, 920. DOI: 10.3969/j.issn.1672-9455.2020.07.014.
[13]	HE Z, YANG DY, FAN XL, et al. The roles and mechanisms of lncRNAs in liver fibrosis[J]. Int J Mol Sci, 2020, 21( 4): 1482. DOI: 10.3390/ijms21041482.
[14]	WANG Y, DENG WP, LI RM. Diagnostic value of serum exosomal LncRNA NEAT 1 for liver fibrosis in patients with nonalcoholic fatty liver disease[J]. Chin J Integr Tradit West Med Liver Dis, 2021, 31( 10): 933- 938. DOI: 10.3969/j.issn.1005-0264.2021.10.018. 王艳, 邓卫平, 李瑞明. 血清外泌体LncRNA NEAT1在非酒精性脂肪性肝病肝纤维化中的诊断价值[J]. 中西医结合肝病杂志, 2021, 31( 10): 933- 938. DOI: 10.3969/j.issn.1005-0264.2021.10.018.
[15]	DANIELS SJ, LEEMING DJ, ESLAM M, et al. ADAPT: An algorithm incorporating PRO-C3 accurately identifies patients with NAFLD and advanced fibrosis[J]. Hepatology, 2019, 69( 3): 1075- 1086. DOI: 10.1002/hep.30163.
[16]	ALKHOURI N, JOHNSON C, ADAMS L, et al. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein levels predict the presence of fibrotic nonalcoholic steatohepatitis(NASH) and NASH cirrhosis[J]. PLoS One, 2018, 13( 8): e0202226. DOI: 10.1371/journal.pone.0202226.
[17]	SIDDIQUI MS, VUPPALANCHI R, van NATTA ML, et al. Vibration-controlled transient elastography to assess fibrosis and steatosis in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2019, 17( 1): 156- 163. e 2. DOI: 10.1016/j.cgh.2018.04.043.
[18]	TAPPER EB, LOOMBA R. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD[J]. Nat Rev Gastroenterol Hepatol, 2018, 15( 5): 274- 282. DOI: 10.1038/nrgastro.2018.10.
[19]	YIN M, GLASER KJ, TALWALKAR JA, et al. Hepatic MR elastography: Clinical performance in a series of 1377 consecutive examinations[J]. Radiology, 2016, 278( 1): 114- 124. DOI: 10.1148/radiol.2015142141.
[20]	FIERBINTEANU-BRATICEVICI C, ANDRONESCU D, USVAT R, et al. Acoustic radiation force imaging sonoelastography for noninvasive staging of liver fibrosis[J]. World J Gastroenterol, 2009, 15( 44): 5525- 5532. DOI: 10.3748/wjg.15.5525.
[21]	GAO F, HUANG JF, ZHENG KI, et al. Development and validation of a novel non-invasive test for diagnosing fibrotic non-alcoholic steatohepatitis in patients with biopsy-proven non-alcoholic fatty liver disease[J]. J Gastroenterol Hepatol, 2020, 35( 10): 1804- 1812. DOI: 10.1111/jgh.15055.
[22]	RAVAIOLI F, DAJTI E, MANTOVANI A, et al. Diagnostic accuracy of FibroScan-AST(FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: A systematic review and meta-analysis[J]. Gut, 2023, 72( 7): 1399- 1409. DOI: 10.1136/gutjnl-2022-328689.
[23]	NEWSOME PN, SASSO M, DEEKS JJ, et al. FibroScan-AST(FAST) score for the non-invasive identification of patients with non-alcoholic steatohepatitis with significant activity and fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 4): 362- 373. DOI: 10.1016/S2468-1253(19)30383-8.
[24]	van DIJK AM, VALI Y, MAK AL, et al. Systematic review with meta-analyses: Diagnostic accuracy of FibroMeter tests in patients with non-alcoholic fatty liver disease[J]. J Clin Med, 2021, 10( 13): 2910. DOI: 10.3390/jcm10132910.
[25]	GUHA IN, PARKES J, RODERICK P, et al. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers[J]. Hepatology, 2008, 47( 2): 455- 660. DOI: 10.1002/hep.21984.
[26]	HARRISON SA, RATZIU V, BOURSIER J, et al. A blood-based biomarker panel(NIS4) for non-invasive diagnosis of non-alcoholic steatohepatitis and liver fibrosis: A prospective derivation and global validation study[J]. Lancet Gastroenterol Hepatol, 2020, 5( 11): 970- 985. DOI: 10.1016/S2468-1253(20)30252-1.
[27]	HARRISON SA, RATZIU V, MAGNANENSI J, et al. NIS2+™, an optimisation of the blood-based biomarker NIS4^® technology for the detection of at-risk NASH: A prospective derivation and validation study[J]. J Hepatol, 2023, 79( 3): 758- 767. DOI: 10.1016/j.jhep.2023.04.031.
[28]	ANGELINI G, PANUNZI S, CASTAGNETO-GISSEY L, et al. Accurate liquid biopsy for the diagnosis of non-alcoholic steatohepatitis and liver fibrosis[J]. Gut, 2023, 72( 2): 392- 403. DOI: 10.1136/gutjnl-2022-327498.
[29]	CANIVET CM, ZHENG MH, QADRI S, et al. Validation of the blood test MACK-3 for the noninvasive diagnosis of fibrotic nonalcoholic steatohepatitis: An international study with 1924 patients[J]. Clin Gastroenterol Hepatol, 2023, 21( 12): 3097- 3106. e 10. DOI: 10.1016/j.cgh.2023.03.032.
[30]	TAVAGLIONE F, JAMIALAHMADI O, VINCENTIS AD, et al. Development and validation of a score for fibrotic nonalcoholic steatohepatitis[J]. Clin Gastroenterol Hepatol, 2023, 21( 6): 1523- 1532. e 1. DOI: 10.1016/j.cgh.2022.03.044.
[31]	YOUNES R, CAVIGLIA GP, GOVAERE O, et al. Long-term outcomes and predictive ability of non-invasive scoring systems in patients with non-alcoholic fatty liver disease[J]. J Hepatol, 2021, 75( 4): 786- 794. DOI: 10.1016/j.jhep.2021.05.008.
[32]	DECHARATANACHART P, CHAITEERAKIJ R, TIYARATTANACHAI T, et al. Application of artificial intelligence in chronic liver diseases: A systematic review and meta-analysis[J]. BMC Gastroenterol, 2021, 21( 1): 10. DOI: 10.1186/s12876-020-01585-5.
[33]	DECHARATANACHART P, CHAITEERAKIJ R, TIYARATTANACHAI T, et al. Application of artificial intelligence in non-alcoholic fatty liver disease and liver fibrosis: A systematic review and meta-analysis[J]. Therap Adv Gastroenterol, 2021, 14: 17562848211062807. DOI: 10.1177/17562848211062807.
[34]	WANG YK, WEI SY, LIU C, et al. A new definition of fatty liver disease: from nonalcoholic fatty liver disease to metabolic associated fatty liver disease[J]. Chin J Dig Surg, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080. 王永康, 魏诗雨, 刘昌, 等. 脂肪性肝病新定义:从非酒精性脂肪性肝病到代谢功能障碍相关脂肪性肝病[J]. 中华消化外科杂志, 2023, 22( S1): 117- 121. DOI: 10.3760/cma.j.cn115610-20230909-00080.
[35]	QADRI S, AHLHOLM N, LØNSMANN I, et al. Obesity modifies the performance of fibrosis biomarkers in nonalcoholic fatty liver disease[J]. J Clin Endocrinol Metab, 2022, 107( 5): e2008- e2020. DOI: 10.1210/clinem/dgab933.
[36]	NOUREDDIN M, MENA E, VUPPALANCHI R, et al. Increased accuracy in identifying NAFLD with advanced fibrosis and cirrhosis: Independent validation of the Agile 3+ and 4 scores[J]. Hepatol Commun, 2023, 7( 5): e0055. DOI: 10.1097/HC9.0000000000000055.

Relative Articles

Supplements(0)

Cited By

Proportional views

Proportional views

通讯作者: 陈斌, bchen63@163.com

1.
沈阳化工大学材料科学与工程学院沈阳 110142

Tables(1)

Get Citation

PDF

XML

Article Metrics

Article views (286) PDF downloads(42)

Research advances of noninvasive diagnosis of fibrotic non-alcoholic steatohepatitis

DOI: 10.12449/JCH241125

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

Research advances of noninvasive diagnosis of fibrotic non-alcoholic steatohepatitis

DOI: 10.12449/JCH241125

Abstract

References

Proportional views

Catalog

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Proportional views

Related

About Journal

Submission Guideline

Journal Online

Hepatobiliary College

Guidelines

Export File

Citation

Format

Content